Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Chinese Journal of Contemporary Pediatrics ; (12): 426-430, 2019.
Article in Chinese | WPRIM | ID: wpr-774059

ABSTRACT

OBJECTIVE@#To study the clinical value of combined measurement of fractional exhaled nitric oxide (FeNO) and nasal fractional exhaled nitric oxide (FnNO) and its correlation with the level of asthma control.@*METHODS@#A total of 120 children who were diagnosed with asthma from January to June, 2018 and were in the chronic persistent stage were enrolled as subjects. The childhood asthma control test (C-ACT) was performed for all the 120 children. According to the C-ACT score, these children were divided into 4 groups: complete control group with a C-ACT score of >23, partial control group with a C-ACT score of 20-23, and uncontrolled group with a C-ACT score of ≤19 (n=40 each). According to the presence or absence of allergic rhinitis, they were divided into 2 groups: non-rhinitis group with 55 children and rhinitis group with 65 children. A total of 40 children who underwent physical examination during the same period of time were enrolled as the control group. FeNO and FnNO levels were measured for all the 120 children.@*RESULTS@#The uncontrolled group had the highest level of FeNO, followed by the partial control group and the complete control group (P<0.05). The uncontrolled and partial control groups had a significantly higher level of FeNO than the control group (P<0.05). The uncontrolled and partial control groups had a significantly higher level of FnNO than the complete control and control groups (P<0.05). The rhinitis group had significantly higher FeNO and FnNO levels than the non-rhinitis group (P<0.05).@*CONCLUSIONS@#FeNO can be used to assess the level of asthma control in children, and its combination with FnNO may be useful for the evaluation of the degree of inflammation in the upper and lower airways and provide a basis for the combined treatment of the upper and lower airways.


Subject(s)
Humans , Asthma , Breath Tests , Nitric Oxide , Rhinitis, Allergic
2.
International Eye Science ; (12): 2151-2153, 2017.
Article in Chinese | WPRIM | ID: wpr-669240

ABSTRACT

AIM:To investigate the correlation between carotid artery disease and fundus arteriosclerosis in patients with cerebral infarction.METHODS:Totally 120 patients with acute cerebral infarction were randomly divided into two groups.The patients were diagnosed with bilateral carotid artery and non-mydriatic fundus camera.Fouty-two patients transient ischaemic attack (TIA) underwent cerebral angiography.The data were recorded for analysis.RESULTS:The degree of fundus arteriosclerosis in patients with cerebral infarction was positively correlated with blood pressure (r=0.361,P=0.015).There was a significant correlation between retinal arteriosclerosis grade and carotid atherosclerosis (r=0.392,P =0.011).The degree of fundus arteriosclerosis was correlated with cerebral arteriolar lesion,higher than it with carotid artery disease (r=0.465,0.392,P=0.037).CONCLUSION:Carotid arteriosclerosis,fundus arteriosclerosis and cerebral arteriolar lesions in patients with cerebral infarction have a significant correlation with hypertension,and fundus arterial examination has important clinical value in judging cerebral arteriosclerosis.

3.
Chongqing Medicine ; (36): 2917-2919, 2016.
Article in Chinese | WPRIM | ID: wpr-497244

ABSTRACT

Objective To analyze the change of chromosome test level after participating in the inter‐laboratory proficiency test(PT) program of the College of American Pathologists (CAP) .Methods The results for participating in CAP PT during 2011-2014 were analyzed ,the accuracy of the cytogenetic chromosome quality control test in this laboratory was obtained accord‐ing to the CAP evaluation results ,and the effect of CAP external quality assessment item on increasing the chromosome detection level in this laboratory was evaluated by analyzing the chromosome band levels before and after participating in CAP .Results This laboratory participated in CAP PT test for 10 times during 2011-2014 ,a total of 59 cases were analyzed ,the accuracy rate for jud‐ging chromosome karyotype was 100% ,the karyotype description accuracy rate was 95 .1% .The chromosome test results of clinical cases in this laboratory displayed that peripheral blood chromosome abnormal detection rate was 18 .9% and bone marrow chromo‐some abnormal detection rate was 25 .9% ,the abnormal rate of newly diagnosed leukemia was 66 .8% ;the detection failure rates of peripheral blood chromosome and bone marrow chromosome were 0 .5% and 5 .0% respectively ;the detection failure rates of pe‐ripheral blood chromosome and bone marrow chromosome after participating in CAP were decreased ,the chromosome band average level was improved ,showing statistical difference compared with those before participating in CAP (P<0 .01) .Conclusion Partici‐pating in high quality external laboratory assessment item can increase the clinical analytic level of cytogenetic chromosome test .

4.
Chinese Journal of Hepatology ; (12): 826-831, 2015.
Article in Chinese | WPRIM | ID: wpr-303223

ABSTRACT

<p><b>OBJECTIVE</b>To investigate the efficacy and related factors of pegylated-interferon alpha-2a (PEG-IFN-2a) treatment in patients with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) who achieved partial viral response with nucleoside analogue (NA) therapy.</p><p><b>METHODS</b>Patients with HBeAg-positive CHB and partial viral response to NA treatment were administered a PEG-IFN-2a therapy regimen of 180 g subcutaneous injection once weekly for a personlized duration of time. The existing NA therapy was continued in combination with the new PEG-IFN-2a treatment for 12 weeks. Measurements of serum HBV DNA load, hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs), HBeAg and hepatitis B e antibody (anti-HBe) were taken at baseline (prior to addition of the PEG-IFN-2a therapy) and every 3 months afterwards.For determining response to treatment, primary efficacy was defined as undetectable HBsAg and seroconversion, and secondary efficacy was defined as HBsAg less than 10 IU/mL and HBeAg seroconversion.Statistical analysis was carried out using SPSS statistical software.</p><p><b>RESULTS</b>A total of 81 consecutive patients with an average of 12.0 months (range: 6.0-24.0 months) of NA therapy were included in the study and received an average of 19.6 months (range: 15.5-33.3 months) of PEG-IFN-2a treatment. At the end of PEG-IFN-2a therapy, 7 (8.6%) of the patients achieved undetectable HBsAg and seroconversion, and 14 (17.3%) showed HBsAg less than 10IU/mL. In addition, 40.7% achieved undetectable HBeAg and seroconversion, a rate that was slightly higher than that (38.3%) seen in treatment-naive patients who received PEG-IFN-2a. Statistical analyses suggest that baseline level of HBsAg at less than 1500 IU/mL may predict end of PEG-IFN-2a treatment response for HBsAg less than 10 IU/mL, as evidenced by the area under the curve measure of 0.747, sensitivity measure of 87.3%, specificity measure of 33.3%, positive predictive value of 82.1% and negative predictive value of 42.8%.</p><p><b>CONCLUSION</b>Patients with HBeAg-positive CHB and partial viral response to NA therapy can achieve undetectable HBsAg and HBeAg seroconversion after switching to PEG-IFN-2a treatment. Baseline HBsAg level may be predictive of response to this therapeutic strategy.</p>


Subject(s)
Humans , Antiviral Agents , Therapeutic Uses , DNA, Viral , Blood , Hepatitis B Antibodies , Blood , Hepatitis B Surface Antigens , Blood , Hepatitis B e Antigens , Blood , Hepatitis B, Chronic , Drug Therapy , Interferon-alpha , Therapeutic Uses , Nucleosides , Therapeutic Uses , Polyethylene Glycols , Therapeutic Uses , Recombinant Proteins , Therapeutic Uses , Sensitivity and Specificity , Treatment Outcome , Viral Load
5.
Chinese Journal of Experimental and Clinical Virology ; (6): 266-269, 2013.
Article in Chinese | WPRIM | ID: wpr-318046

ABSTRACT

<p><b>OBJECTIVE</b>To explore the etiology of acute hepatitis hospitalized patients in Beijing Ditan Hospital from 2002 to 2011.</p><p><b>METHODS</b>We summed up the changes in the characteristics of the etiology of acute hepatitis of patients mentioned above, and preliminarily analyze the causes.</p><p><b>RESULTS</b>From 2002 to 2011, 6235 patients with acute hepatitis were admitted to Ditan Hospital, aged between 12 and 78 years old, Of which 4309 were male and 1926 female. Acute viral hepatitis accounted for 70.44%-85.07%, while CMV, EBV, drug-induced liver injury accounted less than 5%, and acute hepatitis D and acute hepatitis C less than 1.10%. From year to year, the incidence and constitution of acute hepatitis changed significantly. The proportion of patients with acute hepatitis in total hospitalized patients was from 20. 38% to 2.05%. In 10 years, the percentage of acute hepatitis A decreased most obviously, about 99.11%, while 45.07% decline in incidence of acute hepatitis B and 62. 28% of acute hepatitis E. The constituent ratio of acute hepatitis also changed significantly. The proportion of acute hepatitis A declined from 31.31% in 2002, to less than 1% in 2011. The proportion of acute hepatitis B increased from 26.47% in 2002 to 45.88% in 2011, an increase of about 2 folds in 10 years. The proportion of acute hepatitis E increased from 26.73% in 2002 to 32.05% in 2010, a rise of 1.20 times in 10 years.</p><p><b>CONCLUSIONS</b>The proportion of patients with acute hepatitis in total hospitalized patients decreased from 20. 38% in 2002 to 2. 05% in 2011 in Beijing Ditan Hospital. The constituent ratio of acute hepatitis changed, too.</p>


Subject(s)
Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , Young Adult , Acute Disease , Epidemiology , China , Epidemiology , Hepatitis, Viral, Human , Epidemiology , Virology , Hospitalization , Viruses , Classification , Genetics
6.
Chinese Journal of Experimental and Clinical Virology ; (6): 366-369, 2013.
Article in Chinese | WPRIM | ID: wpr-318018

ABSTRACT

<p><b>OBJECTIVE</b>A retrospective study was conducted to investigate the clinical features and prognostic factors of 73 cases of severe hepatitis.</p><p><b>METHODS</b>To summarize clinical features of 73 cases of severe hepatitis, grouping by etiology and pathogenesis. A retrospective analysis was performed to evaluate the relationship between biochemical characteristics (liver function, renal function, electrolytes, PTA, etc) and complications (hepatic encephalopathy, upper gastrointestinal bleeding, hepatorenal syndrome, ascites, abdominal infections, etc) and prognosis.</p><p><b>RESULTS</b>(1) HBV infection alone accounted for 65.75%. Alcoholic liver disease, drug-induced liver injury, hepatitis E, autoimmune hepatitis, overlapping causes and other factors were five cases (6.85%), six cases (8.22%), two cases (2.74%), two cases (2.74%), seven cases (9.59%) and three cases (4.11%) respectively. According to the incidence rate, severity and underlying liver condition, subacute hepatitis, cases based on chronic hepatitis and on cirrhosis were 12 cases (16.43%), 11 cases (15.07%), 50 cases (68.49%) respectively. Clinical manifestations with or without hepatic encephalopathy accounted for 58.90% or 41.10%. (2) The highest mortality of severe hepatitis was alcoholic liver disease and patients on the basis of overlapping factors (66.67%), followed by autoimmune liver disease (50%). The mortality of HBV-related hepatitis was 18.75%. Overall mortality of 73 cases of severe hepatitis was 28.77%, of which cirrhosis group was higher than non-cirrhotic group (40% vs 4.3%, P = 0.002). The difference was statistically significant. Patients without hepatic encephalopathy had lower mortality than with hepatic encephalopathy (3.33% vs 46.51%). The mortality of patients with hepatic encephalopathy Stage III and IV was 72.73%. (3) Independent samples t test filtered nine factors associated with death, namely cirrhosis, upper gastrointestinal bleeding, hepatic encephalopathy, hepatorenal syndrome, serum creatinine, total bilirubin (TBIL), direct bilirubin (DBIL), albumin (ALB) and serum sodium. The results of multivariate conditional logistic regression analysis indicated that hepatic encephalopathy, serum creatinine levels were risk factors for death, whereas ALB as a protective factor.</p><p><b>CONCLUSION</b>Hepatic encephalopathy, serum creatinine levels were risk factors for severe hepatitis death, But ALB was protective factor. Nucleotide analogs using was the main reason why the mortality of hepatitis B was as low as 18.75%.</p>


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , Hepatitis , Mortality , Pathology , Virology , Hepatitis B virus , Genetics , Prognosis , Retrospective Studies , Risk Factors
7.
Chinese Journal of Applied Physiology ; (6): 222-226, 2010.
Article in Chinese | WPRIM | ID: wpr-340188

ABSTRACT

<p><b>OBJECTIVE</b>To study the effect of anti-basic jibroblast grouth factor (bFGF) on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism.</p><p><b>METHODS</b>Pulmonary fibrosis was induced in Wistar rats by intratracheal instillation of bleomycin (model group, group M). Then the rats received anti-bFGF on 1, 2, 3, 8, 12, 19, 25 days intracavitary injection (group K), normal saline(group C) orally. Normal controls received normal saline both intratracheally and orally. Five rats in each group were sacrificed on 1.4 week after intratracheal instillation. Histological changes of the lungs were evaluated by HE stain and Massons trichrome stain. Lung expression of bFGF proteins was assessed by immunohistochemistry and the level of bFGF protein in serum and BALF was further measured by ELISA.</p><p><b>RESULTS</b>Pulmonary fibrosis of group M was higher than that of group C. bFGF in group M was higher than that in group C in lung, serum and BALF on 1.4 week. Pulmonary fibrosis of group K was lower than that of group M. bFGF in group K was lower than that in group M in lung, serum and BALF on 1.4 week.</p><p><b>CONCLUSION</b>Anti-bFGF alleviates bleomycin-induced pulmonary fibrosis in rats. Inhibiting the expressions of bFGF in lung tissues may be one of the mechanisms.</p>


Subject(s)
Animals , Female , Rats , Antibodies , Allergy and Immunology , Pharmacology , Bleomycin , Fibroblast Growth Factor 2 , Allergy and Immunology , Pulmonary Fibrosis , Metabolism , Random Allocation , Rats, Wistar
8.
Chinese Journal of Applied Physiology ; (6): 330-333, 2010.
Article in Chinese | WPRIM | ID: wpr-340158

ABSTRACT

<p><b>OBJECTIVE</b>To study the effect of inhalation of glucocorticoid on bleomycin-induced pulmonary fibrosis in rats and its possible mechanism.</p><p><b>METHODS</b>Pulmonary fibrosis was induced in Wistar rats by intratracheal instillation of bleomycin (group M, group B, group D). Group B inhaled glucocorticoid daily from the next day of received bleomycin. Group D intraperitoneal injection glucocorticoid daily from the next day of received bleomycin. Normal controls received normal saline both intratracheally. Five rats in each group were killed at 1, 4 week after intratracheal instillation. Histological changes of the lungs were evaluated by HE, Masson trichrome stain. Lung expression of bFGF proteins was assessed by immunohistochemistry and the level of bFGF protein in serum and BALF was further measured by ELISA.</p><p><b>RESULTS</b>Pulmonary fibrosis of group M was higher than that of group C, pulmonary fibrosis of group B, D was lower than that of group M at 1, 4 week. bFGF in group M was higher than that in group C, bFGF in group B, D was lower than that in group M in lung, serum and BALF on 1, 4 week.</p><p><b>CONCLUSION</b>Inhalation of glucocorticosteroid alleviates bleomycin-induced pulmonary fibrosis in rats. The mechanism may be related to the changes that bFGF is degrade or prevent it step up.</p>


Subject(s)
Animals , Male , Rats , Administration, Inhalation , Fibroblast Growth Factor 2 , Metabolism , Glucocorticoids , Therapeutic Uses , Pulmonary Fibrosis , Drug Therapy , Metabolism , Pathology , Rats, Wistar
9.
Chinese Acupuncture & Moxibustion ; (12): 449-452, 2010.
Article in Chinese | WPRIM | ID: wpr-285122

ABSTRACT

<p><b>OBJECTIVE</b>To compare the difference of therapeutic effects between vessel pricking therapy and Prednisone for treatment of Henoch-Schonlein purpura nephritis.</p><p><b>METHODS</b>Seventy cases of acute purpura nephritis syndrome were randomly divided into an observation group (40 cases) and a control group (30 cases). Patients in observation group were differentiated into sthenia and asthenia syndromes. Vessel pricking therapy was applied at Hegu (LI 4), Quchi (LI 11), Xuehai (SP 10) etc. by triangular needle for sthenia symptom; shallow needling was used at Pishu (BL 20), Shenshu (BL 23), Zusanli (ST 36) etc. by filiform needle. The control group was treated with oral admi-nidtration of Prednisone. The symptom score of TCM, 24 h urinary protein, red blood cell count of urinary sediment of both groups were observed before and after treatment and therapeutic effects were compared.</p><p><b>RESULTS</b>The total effective rate of 92.5% (37/40) in observation group was superior to that of 80.0% (24/30) in control group, and there was a significant difference between two groups (P < 0.05); the symptom score of TCM, 24 h urinary protein, red blood cell count of urinary sediment were all improved in both groups after treatment (all P < 0.05), and moreover, the improvement in observation group was superior to that of control group (all P < 0.05); after treatment, the symptom score of TCM of sthenia syndrome was lower than that of asthenia syndrome in observation group (P < 0.05).</p><p><b>CONCLUSION</b>Vessel pricking therapy has a significant therapeutic effect for treatment of Henoch-Schonlein purpura nephritis, superior to that of oral administration of Prednisone, and the therapeutic effect is better for treating sthenia syndrome than for asthenia syndrome.</p>


Subject(s)
Adolescent , Adult , Child , Female , Humans , Male , Middle Aged , Young Adult , Acupuncture Points , Blood Sedimentation , Bloodletting , Erythrocyte Count , Prednisone , Therapeutic Uses , IgA Vasculitis , Blood , Drug Therapy , Therapeutics , Urine , Chemistry
SELECTION OF CITATIONS
SEARCH DETAIL